January 2023
| No | Study Name/Phase | Type | Sponsor | Population (Gender/Age) | Enrolled / (Target if still enrolling) | Period |
| Setshaba Research Centre: Site Initiated Research | ||||||
| 1 |
Vaccine Hesitancy |
Behavioural | SRC | ♂/♀≥18 | n/a | 2022 |
| 2 | HVTN 702/705 Mapping click to read more | Behavioural | SRC | ♂/♀18-35 yrs | n/a | 2020-2021 |
| Other Projects | ||||||
| 3 | R01 AI147681 KHARITUWE TB MIGRATION STUDY | TB Tracing | John Hopkins University | ♂/♀ 0-99 yr target target | target 7200 | 2020 – 2025 |
| 4 | C3671008 | RSV Vaccine | Pfizer | ♀ ≥18 and ≤49 | target 120 | 2020 – 2023 |
| 5 | VAC31518COV3001 | Covid Vaccine | Janssen | ♂+♀
≥18 and ≤60 & ≥60 |
306 | 2020 – 2022 |
| 6 | CoVPN5001 / HVTN5001 | Covid observational | CoVPN | ♂+♀ ≥18 | Target 15 | 2020 – 2021 |
| 7 | ACTIV-2 A5401 | COVID IV Infusion | PPD | ♂+♀ ≥18 | Target 75 | 2021 – 2022 |
| 8 | 212171 (RSV MAT-009) | RSV Vaccine | GSK | ♀ 18 – 49 | Target 250 | 2021 – 2023 |
| 9 | MK8591-022 IMPOWER | Oral PrEP | MSD | ♀ 18 – 45 | Target 300 | 2021 – 2025 |
| 10 | HVTN RAMP | Behavioural | HVTN | MSM &Transgender ♂ ≥18;
Transgender ♀ ≥18 |
200 | May 2021 – May 2022 |
| 11 | Sisonke VAC31518COV3012 Phase 3b | Covid Vaccine | Janssen | ♂+♀ 18-65 |
600 000 | Feb/ 2021 – Feb/2023 |
| 12 | STI Zoli Study Phase 3 | STI Treatment Oral/Intramuscular | GARDP | ≥ 12♂/♀ | 80 | Nov/2021 – Dec/2021 |
| 13 |
GS-US-412-5624 (PURPOSE 1)
|
HIV PrEP study | Gilead | Cisgender ♀ 16 – 35 |
200 | Nov/2021 – Jun/2026 |
| 14 | HVTN 139 Phase 1 | HIV Vaccine Study | HVTN | ♂+♀18 through to 50 years | 6 | Nov/2021 – Dec/2023 |
| 15 | Pfizer RSV Phase 3 | RSV Vaccine | Pfizer | ♂+♀ ≥ 60 |
100 | Nov/2021 – Dec/2022 |
| 16 | C3671013 | RSV Vaccine | Pfizer | ♂+♀ 60-70 | 4 | Dec2021- 2023 |
| 17 | Gates MRI TBV02-EO1 | Epidemiology | Bill and Melinda Gates | ♂+♀15 – 34 | 160 | Jan 2022 – Jun 2025 |
| 18 | VAC31518COV3003 | Covid Vaccine | Janssen | ♂+♀18 -55 | 100 | Feb 2022- May 2023 |
| 21 | GO-012 | Covid Vaccine | Gritstone Bio | ♂+♀18 – 64 | 120 | Mar 2022 – Mar 2023 |
| 22 | 323-201-00006_Otsuka Trial – 2b/TB | TB Oral treatment Study | Clindev | ♂+♀ 18-65 | 20 | APR/2022-APR/2024 |
| 23 | GS-US-528-9023_(Purpose 2) | HIV PrEP study | Gilead | Cisgender ♀
16 – 35 |
75 | Jul 2022 – 2026 |
| 24 | VAC31518COV3006_Horizon 2 | Covid Vaccine | Janssen | <12 years
≥18 |
16 | Jun 2022 – Jun 2024 |
| 25 | Sisonke 4 (SHERPA) mRNA-1273-P508 | Covid Vaccine | SAMRC | ♂+♀18 and above | 500 | Jun 2022- Sep 2022 |
| 25 | Alvea-Vax | Covid vaccine | Alvea LLC & Telis Bioscience Inc. | ♂+♀
18 – 65 years |
18 | Jun 2022 – Oct 2023 |
| 26 | GBS_MVX0004 | Group B Streptococcus | MinerVax/OnQ | ♀
18 years and older |
50 | Aug 2022-Aug 2023 |
| 27 | Insight | HIV PrEP study university | University of Washington | ♀
16 – 30 years |
150 | Sep 2022 – 2023 |
OUR EXPERIENCE
COVID-19
Areas of Expertise
Completed Projects
Current Projects